摘要
目的:评价加味小柴胡汤在改善原发性肝癌患者经动脉化疗栓塞术(TACE)后综合症状的疗效。方法:本研究于2020年10月~2022年9月共选取接受TACE治疗的原发性肝癌患者92例。按照抽签法分为试验组和对照组,每组60例。对照组采取标准术后治疗,而试验组在常规治疗的基础上额外使用加味小柴胡汤进行治疗。对比两组在症状缓解时间(肝区疼痛、发热、便秘、恶心、呕吐)、治疗效果、中医证候评分、肝功能指标(AST、γ-GT、ALT、ALP、TBil)、血管生成和细胞外基质调节因子[碱性成纤维细胞生长因子(bFGF)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)]、症状干扰程度[M.D.Anderson症状调查量表(MDASI)]评分、生活质量[卡氏功能状态(KPS)评分]上的差异。结果:试验组在症状缓解时间上短于对照组(P<0.05);试验组在治疗总有效率上高于对照组(P<0.05);试验组在中医证候评分和AST、γ-GT、ALT、TBil水平上低于对照组(P<0.05);试验组在bFGF、MMP-9、VEGF水平上低于对照组(P<0.05);试验组在MDASI评分上低于对照组,在KPS评分上高于对照组(P<0.05)。结论:加味小柴胡汤能有效缩短TACE术后原发性肝癌患者的症状缓解时间,提升治疗有效率,改善肝功能,并减少血管新生相关因子,提高患者生活质量,对改善TACE术后综合征具有重要价值。
Objective:To evaluate the clinical efficacy of Modified Xiaochaihu Tang on post-transarterial chemoembolization(TACE)syndrome in patients with primary liver cancer.Methods:This study,conducted from October 2020 to September 2022,included 92 primary liver cancer patients who underwent TACE treatment.The patients were divided into a trial group(n=46)and a control group(n=46)using stratified random sampling.The control group received routine postoperative treatment,while the trial group was additionally treated with Modified Xiaochaihu Tang.Comparisons were made between the two groups in terms of symptom relief duration(liver pain,fever,constipation,nausea,vomiting),treatment efficacy,Traditional Chinese Medicine(TCM)symptom scores,liver function indicators[aspartate aminotransferase(AST),gamma-glutamyl transferase(γ-GT),alanine aminotransferase(ALT),alkaline phosphatase(ALP),total bilirubin(TBil)],angiogenesis and extracellular matrix regulation factors[basic fibroblast growth factor(bFGF),matrix metallopeptidase-9(MMP-9),vascular endothelial growth factor(VEGF)],symptom interference[M.D.Anderson Symptom Inventory(MDASI)scores],and quality of life[Karnofsky Performance Status(KPS)score].Results:The trial group had a shorter duration of symptom relief compared to the control group(P<0.05);higher overall treatment efficacy(P<0.05);lower TCM symptom scores and levels of AST,γ-GT,ALT,TBil(P<0.05);lower levels of bFGF,MMP-9,VEGF(P<0.05);and lower MDASI scores,with higher KPS scores compared to the control group(P<0.05).Conclusion:Modified Xiaochaihu Tang effectively reduces the symptom relief duration,improves treatment efficacy,enhances liver function,reduces angiogenesis-related factors,and improves quality of life in patients with primary liver cancer following TACE.It is of significant value in improving post-TACE syndrome.
作者
孙明令
周为
SUN Mingling;ZHOU Wei(Chongqing Traditional Chinese Medicine Hospital,Chongqing,400021,China)
出处
《四川中医》
2024年第9期148-152,共5页
Journal of Sichuan of Traditional Chinese Medicine
基金
重庆市科卫联合中医药技术创新与应用发展项目(编号:2021ZY4092)。
